DERMHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Journey Medical Corp. hold a median 12-month price target of $14 — +86.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Journey Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Accruals (18): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DERM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +86.7% from it.
Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Aug 2026 | B. Riley Securities | Reiterates | Buy | $12 → $15 |
| 26 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | $13 |
| 26 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Aug 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 13 Aug 2025 | Lake Street | Maintains | Buy | — |
| 30 July 2025 | B. Riley Securities | Maintains | Buy | — |
| 6 Sept 2024 | Lake Street | Initiates | Buy | $9.00 |
| 22 Aug 2024 | Rodman & Renshaw | Initiates | Buy | $9.00 |
| 28 June 2024 | Roth MKM | Reinstates | Buy | $11 |
| 16 Feb 2024 | Alliance Global Partners | Initiates | Buy | — |
| 7 Sept 2023 | B. Riley Securities | Reiterates | Buy | — |
| 12 July 2023 | B. Riley Securities | Maintains | Buy | — |
| 23 May 2023 | B. Riley Securities | Maintains | Buy | — |
| 30 Mar 2023 | B. Riley Securities | Reiterates | Buy | — |
| 25 Feb 2022 | Cantor Fitzgerald | Initiates | Overweight | — |
| 16 Dec 2021 | Roth Capital | Initiates | Buy | — |
| 7 Dec 2021 | B. Riley Securities | Initiates | Buy | — |
| 6 June 2019 | Mizuho | Upgrade | Buy | $17 → $14 |
| 6 Mar 2018 | Mizuho | Downgrade | Neutral | $39 → $9.00 |
| 16 Mar 2016 | Citigroup | Maintains | Buy | $42 → $40 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DERM appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, Journey Medical Corp. returned −1.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 41% of US stocks
Cheaper than 16% of US stocks
Cheaper than 2% of US stocks
Higher than 73% of US stocks
Higher than 61% of US stocks
Higher than 80% of US stocks
Higher than 49% of US stocks
Higher than 21% of US stocks
Higher than 30% of US stocks
Higher than 37% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Journey Medical Corp. has a market value of $204.1M and an enterprise value of $204.0M.
Revenue in the twelve months to 30 June 2026: $68.2M. The latest quarter grew 23.3% year on year.
Net income over the same four quarters: −$6.1M, a −9.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$7.5M.
Trailing P/E: 39.1×; forward P/E: −120.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Journey Medical Corp. employs 58 people — $1.2M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Journey Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Journey Medical Corporation announced that its Co-Founder, President and CEO, Claude Maraoui, will participate in two investor conferences in September 2026. The announcement was made via GlobeNewsWire on September 8, 2026.
Why it matters — Investor conference participation gives DERM watchers a scheduled opportunity to hear directly from company leadership about the business.
Zacks Investment Research published a comparison of Elite Pharmaceuticals and Journey Medical Corp., examining how the two specialty pharmaceutical companies follow different growth paths and which appears more compelling to investors at this time.
Why it matters — The comparison offers Journey Medical investors a view of how the company is positioned against a peer within the specialty pharmaceutical sector.
Journey Medical's Q2 report showed Emrosi prescription growth rebounding from Q1 lows, with revenues up 23% to $18.5M and positive EBITDA. Prescribers rose over 40% quarter-over-quarter, formulary coverage improved from 34% to 38%, and cost discipline was evident as SG&A declined.
Why it matters — The report confirms DERM's thesis is on track as the Emrosi franchise gains traction through rising prescribers, improved formulary coverage, and disciplined costs.
Journey Medical Corporation held its Q2 2026 earnings call, with the transcript published on Seeking Alpha.
Why it matters — DERM watchers would care because earnings calls provide direct insight into the company's financial performance and strategic outlook.
A Zacks Research report discusses Journey Medical Corp.'s (DERM) headline results for the quarter ended June 2026, suggesting it may be useful to compare some of the company's key metrics against Wall Street estimates and year-ago actuals.
Why it matters — DERM watchers would care because comparing key quarterly metrics to analyst estimates and prior-year results offers insight into how the company performed in the June 2026 quarter.
The 4 Wall Street analysts covering Journey Medical Corp. have a median 12-month price target of $14, with estimates ranging from $13 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Journey Medical Corp., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Journey Medical Corp. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, Journey Medical Corp. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +86.7% from the last close, and Ticker Nerd's factor model ranks Journey Medical Corp. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Journey Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DERM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $15 over the next 12 months.
Journey Medical Corp. returned -1.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Journey Medical Corp. Common Stock represents the equity of Journey Medical Corporation, a commercial-stage pharmaceutical company focused on developing, marketing, and selling prescription products for dermatological conditions in the United States.
The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Journey Medical Corporation to Participate in September 2026 Investor Conferences". Journey Medical Corporation announced that its Co-Founder, President and CEO, Claude Maraoui, will participate in two investor conferences in September 2026. The announcement was made via GlobeNewsWire on September 8, 2026.
Journey Medical Corp. Common Stock represents the equity of Journey Medical Corporation, a commercial-stage pharmaceutical company focused on developing, marketing, and selling prescription products for dermatological conditions in the United States. The company’s portfolio includes branded and authorized generic treatments used in areas such as acne, hyperhidrosis, fungal infections, and other skin disorders. Its current product lineup includes therapies such as Qbrexza, Accutane, Amzeeq, Targadox, Ximino, Zilxi, Exelderm, and Luxamend, reflecting a business centered on specialty dermatology care. Journey Medical Corp. serves a focused market within the broader pharmaceutical sector by commercializing FDA-approved products designed for physician-prescribed use. The stock is associated with a small-cap healthcare company whose role in the market is tied to the distribution and commercialization of dermatology medicines rather than broad consumer health products.
CEO Mr. Claude Maraoui · 58 employees · United States · https://journeymedicalcorp.com
